MENU
+Compare
DARE
Stock ticker: NASDAQ
AS OF
Dec 20 closing price
Price
$2.71
Change
-$0.27 (-9.06%)
Capitalization
23.53M

DARE Dare Bioscience Inc. Forecast, Technical & Fundamental Analysis

a provider of pharmaceutical products

Industry Biotechnology
DARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for DARE with price predictions
Dec 20, 2024

DARE in upward trend: price expected to rise as it breaks its lower Bollinger Band on December 19, 2024

DARE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 28 cases where DARE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for DARE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where DARE advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on DARE as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for DARE turned negative on December 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

DARE moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for DARE crossed bearishly below the 50-day moving average on November 25, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DARE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for DARE entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.267) is normal, around the industry mean (14.556). P/E Ratio (0.099) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). DARE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (12.005) is also within normal values, averaging (256.215).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
DARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

DARE is expected to report earnings to fall 133.29% to 2 cents per share on August 08

Dare Bioscience Inc. DARE Stock Earnings Reports
Q2'24
Est.
$0.02
Q1'24
Missed
by $0.01
Q4'23
Beat
by $0.02
Q3'23
Beat
by $0.01
Q2'23
Est.
$-0.10
The last earnings report on May 14 showed earnings per share of -7 cents, missing the estimate of -5 cents. With 89.97K shares outstanding, the current market capitalization sits at 23.53M.
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3655 Nobel Drive
Phone
+1 858 926-7655
Employees
26
Web
https://www.darebioscience.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PTN0.970.11
+12.55%
Palatin Technologies
TECK40.940.95
+2.38%
Teck Resources Limited
PDS56.580.72
+1.29%
Precision Drilling Corp
BLFY9.93N/A
N/A
Blue Foundry Bancorp
ENS92.46-0.05
-0.05%
EnerSys

DARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DARE has been closely correlated with AZTR. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DARE jumps, then AZTR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DARE
1D Price
Change %
DARE100%
-9.06%
AZTR - DARE
73%
Closely correlated
+5.01%
CYTK - DARE
42%
Loosely correlated
+4.56%
AXON - DARE
39%
Loosely correlated
+2.60%
AMRN - DARE
34%
Loosely correlated
-1.18%
SNTI - DARE
32%
Poorly correlated
-0.25%
More

Groups containing DARE

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DARE
1D Price
Change %
DARE100%
-9.06%
DARE
(2 stocks)
33%
Loosely correlated
-2.03%